ICIs targeting programmed cell death protein 1/programmed cell death protein 1 ligand (PD-1/PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) in T cells have revolutionized cancer treatment and have shown impressive clinical results in solid tumours such as melanoma [137]. Here, CTLA4 is linked to melanoma.